Considering the introduction of PSMA theranostics for advanced PCa, further studies are needed to assess FOLH1 vs. SSTR2 over‐expression in blood of patients as indicators of intra‐tumoural heterogeneity and predictors of response to their respective radionuclide therapies [38]. This evidence concerns the gene FOLH1 and posterior cortical atrophy.